Hyamedix ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  12.1% 12.0% 25.1% 32.2% 31.2%  
Credit score (0-100)  21 20 2 0 0  
Credit rating  BB BB B C C  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  1,384 1,402 -2,705 -2,134 48.1  
EBITDA  15.0 -482 -5,582 -4,888 -1,931  
EBIT  15.0 -482 -5,582 -4,888 -1,931  
Pre-tax profit (PTP)  11.5 -486.4 -5,824.8 -5,206.5 -2,451.9  
Net earnings  8.1 -486.4 -5,973.6 -5,206.5 -2,750.6  
Pre-tax profit without non-rec. items  11.5 -486 -5,825 -5,207 -2,452  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  9.1 1,523 -3,855 -5,052 -7,803  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 2,290  
Balance sheet total (assets)  1,098 2,251 3,561 1,853 4,484  

Net Debt  -570 -2,090 -3,381 -1,651 -1,090  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  -100.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,384 1,402 -2,705 -2,134 48.1  
Gross profit growth  292.0% 1.3% 0.0% 21.1% 0.0%  
Employees  2 3 3 3 2  
Employee growth %  0.0% 50.0% 0.0% 0.0% -33.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,098 2,251 3,561 1,853 4,484  
Balance sheet change%  6.2% 105.0% 58.2% -48.0% 141.9%  
Added value  15.0 -481.6 -5,582.1 -4,887.6 -1,930.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  -1.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  1.1% -34.4% 206.4% 229.0% -4,015.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  1.4% -28.8% -115.5% -68.3% -20.1%  
ROI %  58.4% -62.9% -146.1% -159.8% -168.6%  
ROE %  160.5% -63.5% -235.0% -192.3% -86.8%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.8% 67.6% -52.0% -73.2% -63.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -3,799.5% 434.0% 60.6% 33.8% 56.5%  
Gearing %  0.0% 0.0% 0.0% 0.0% -29.4%  
Net interest  0 0 0 0 0  
Financing costs %  17.0% 0.0% 0.0% 0.0% 45.5%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.0 3.1 2.7 3.8 1.2  
Current Ratio  1.0 3.1 2.7 3.8 1.2  
Cash and cash equivalent  569.8 2,090.2 3,381.2 1,650.7 3,380.8  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  9.1 1,522.8 2,261.2 1,364.6 593.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  7 -161 -1,861 -1,629 -965  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  7 -161 -1,861 -1,629 -965  
EBIT / employee  7 -161 -1,861 -1,629 -965  
Net earnings / employee  4 -162 -1,991 -1,736 -1,375